| SPC No. |
Product |
Applicant |
Decision Date |
| 2018/010 |
Cladribine (MAVENCLAD) |
Merck Serone S.A. |
08/10/2025 |
| 2015/043 |
Safinamide for use in combination with levodopa/PDI, and optionally with other PD medicinal products, for the treatment of Parkinson's Disease |
Newron Pharmaceuticals S.p.A |
14/05/2024 |
| 2014/038 |
Dapagliflozin and Metformin (XIGDUO) |
AstraZeneca AB |
24/05/2021 |
| 2017/035 |
Talimogene Iaherparepvec (IMLYGIC) |
Georgetown University |
12/04/2021 |
| 2019/010 |
Binimetinib and Encorafenib (MEKTOVI/BRAFTOVI) |
Array BioPharma Inc |
12/03/2021 |
| 2017/044 |
Obinutuzumab and Bendamustine (GAZYVARO) |
Roche Glycart AG |
19/01/2021 |
| 2009/040 |
Prucalopride (RESOLOR) |
Shire International GmbH |
23/08/2019 |
| 2013/035 |
Insulin degludec and Insulin aspart (RYZODEG) |
Novo Nordisk A/S |
14/01/2019 |
| 2014/050 |
Ezetimibe and Rosuvastatin (VIAZET) |
Merck Sharp & Dohme Corp. |
03/08/2017 |
| 1996/028 |
Losartan potassium (COZAAR) |
E.I. Du Pont De Nemours & Company |
23/09/2009 |
| 1999/002 |
Valsartan (CO-DIOVAN) |
Novartis AG |
10/03/2005 |
